BG99441A - Oral application of antigens - Google Patents

Oral application of antigens

Info

Publication number
BG99441A
BG99441A BG99441A BG9944195A BG99441A BG 99441 A BG99441 A BG 99441A BG 99441 A BG99441 A BG 99441A BG 9944195 A BG9944195 A BG 9944195A BG 99441 A BG99441 A BG 99441A
Authority
BG
Bulgaria
Prior art keywords
antigens
antigen
oral application
intestinal
lymphoid tissues
Prior art date
Application number
BG99441A
Other languages
Bulgarian (bg)
English (en)
Inventor
Terry Bowersock
Waleed Shalaby
William Blevins
Michel Levy
Kinam Park
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of BG99441A publication Critical patent/BG99441A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BG99441A 1992-07-20 1995-02-17 Oral application of antigens BG99441A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/916,533 US5352448A (en) 1992-07-20 1992-07-20 Oral administration of antigens
PCT/US1993/006490 WO1994002170A1 (fr) 1992-07-20 1993-07-09 Administration orale d'antigenes

Publications (1)

Publication Number Publication Date
BG99441A true BG99441A (en) 1995-12-29

Family

ID=25437423

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99441A BG99441A (en) 1992-07-20 1995-02-17 Oral application of antigens

Country Status (8)

Country Link
US (1) US5352448A (fr)
EP (1) EP0652770A4 (fr)
AU (1) AU682150B2 (fr)
BG (1) BG99441A (fr)
MX (1) MX9304346A (fr)
NZ (1) NZ254560A (fr)
RU (1) RU95106976A (fr)
WO (1) WO1994002170A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1120310A (zh) * 1993-03-11 1996-04-10 塞科雷泰克公司 在粘膜表面转运免疫原的聚合粘膜粘合剂
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5674495A (en) * 1995-02-27 1997-10-07 Purdue Research Foundation Alginate-based vaccine compositions
US5800821A (en) * 1995-03-10 1998-09-01 New England Medical Center Hospitals, Inc. Bacterial spores as a heat stable vaccine delivery system
US5750585A (en) * 1995-04-04 1998-05-12 Purdue Research Foundation Super absorbent hydrogel foams
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US6247995B1 (en) 1996-02-06 2001-06-19 Bruce Bryan Bioluminescent novelty items
US6015576A (en) * 1997-08-29 2000-01-18 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to an antigen
AU682805B1 (en) * 1996-03-22 1997-10-16 Biosphere Technologies Inc. Method for inducing a systemic immune response to an antigen
US6207185B1 (en) * 1996-03-22 2001-03-27 Bio-Sphere Technology Method for inducing a systemic immune response to an HIV antigen
US6117449A (en) * 1996-03-22 2000-09-12 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to a hepatitis antigen
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
US5741680A (en) * 1996-09-03 1998-04-21 Cera Products, Inc. Buffer composition base and method of formulation for oral vaccine delivery
AU741076B2 (en) 1996-12-12 2001-11-22 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
US6271278B1 (en) 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
EP1925320A3 (fr) 1998-03-27 2008-09-03 Prolume, Ltd. Luciférases, protéines fluorescentes, acides nucléiques codant pour les luciférases et protéines fluorescentes et leur utilisation pour le diagnostic, le criblage à haut rendement et articles nouveaux
US6521431B1 (en) 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
US6682754B2 (en) * 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
ES2243497T3 (es) 2000-05-12 2005-12-01 PHARMACIA & UPJOHN COMPANY LLC Composicion de vacuna, procedimiento de preparacion de la misma y procedimiento para vacunacion de vertebrados.
US6676958B2 (en) * 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
MXPA05013234A (es) * 2003-06-10 2006-03-09 Univ Saskatchewan Proteinas de capside de adenovirus quimericas.
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US20080292663A1 (en) * 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
US8647640B2 (en) * 2009-06-24 2014-02-11 Richard E. COWART Vaccine compositions and methods of use to protect against infectious disease
US9878036B2 (en) 2009-08-12 2018-01-30 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
WO2013138334A1 (fr) 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Compositions d'adjuvant et de vaccin
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
LT4037666T (lt) 2020-12-08 2024-06-10 Ruminant Biotech Corp Limited Medžiagų pristatymo gyvūnams prietaisų ir būdų patobulinimai

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1586811A (fr) * 1966-01-06 1970-03-06
EG10802A (en) * 1971-02-19 1976-10-31 Bayer Ag A process for embeding veterinary substances and their protection against the influence of the gastric juice of the rumen
US4178361A (en) * 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
GB1440217A (en) * 1973-09-26 1976-06-23 Ici Ltd Compositions
US4220152A (en) * 1978-05-08 1980-09-02 Pfizer Inc. Delivery system
GB8305797D0 (en) * 1983-03-02 1983-04-07 Graham N B Hydrogel-containing envelopes
US4693887A (en) * 1983-09-15 1987-09-15 The Kendall Company Microphase separated hydrogels for controlled release of bioactive materials
US4749576A (en) * 1984-05-10 1988-06-07 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
EP0205336B1 (fr) * 1985-06-11 1991-09-11 Teijin Limited Préparation pharmaceutique orale à effet entretenn
US4780315A (en) * 1985-11-25 1988-10-25 Eastman Kodak Company Rumen-stable pellets
US4801457A (en) * 1986-08-01 1989-01-31 Sandoz Pharm. Corp. Polyacetal hydrogels formed from divinyl ethers and polyols
WO1991016057A1 (fr) * 1990-04-18 1991-10-31 University Of Utah FORMES DE DOSAGE DE MEDICAMENTS ABSORBES PAR VOIE ORALE ET DESTINES A ETRE LIBERES DANS LE COLON, REALISEES A PARTIR D'HYDROGELS RETICULES RENFERMANT DES LIAISONS AZOÏQUES ET PRESENTANT UN GONFLEMENT DEPENDANT DU pH

Also Published As

Publication number Publication date
US5352448A (en) 1994-10-04
MX9304346A (es) 1994-04-29
NZ254560A (en) 1996-12-20
EP0652770A1 (fr) 1995-05-17
WO1994002170A1 (fr) 1994-02-03
RU95106976A (ru) 1997-03-20
AU4671493A (en) 1994-02-14
AU682150B2 (en) 1997-09-25
EP0652770A4 (fr) 1996-05-29

Similar Documents

Publication Publication Date Title
BG99441A (en) Oral application of antigens
NO20083842L (no) Anvendelse av opploselig lymfotoksin-beta-reseptor for fremstilling av medikamenter
MD970199A (en) Induction of a cytotoxic T-lymphocytic answer The invention relates to the medicine, particularly to the immunology and can be used for treatment of bacterial and parasitic infections, tumors and other diseases. The summary of the invention consists in the induction of a cytotoxic T-lymphocytic answer to human and animals by means of a composition consisting of an antigene and an antigenic formulati
AU7589587A (en) Low dosage of interferon to enhance vaccine efficiency
SE8803486L (sv) Dosform foer behandling av kardiovaskulaera sjukdomar
FR2620941B1 (fr) Vaccin contenant des adjuvants et des antigenes tumoraux
CY1106400T1 (el) Συνθεση και μεθοδος ανοσοθepαπειας με καρκινικο αντιγονο
RU2000112547A (ru) Композиции и способы системной доставки пероральных вакцин и терапевтических агентов
GB9818627D0 (en) Improvements in dva vaccination
EP0067130A3 (en) Capsules containing the active principle of an allergen, and process for their preparation
IL83953A (en) Vaccine comprising a bacterial flagella protein conjugated to an antigen and method of preparation
NO177376C (no) Fremgangsmåte for fremstilling av en farmasöytisk doseringsform basert på en tampongtrykkmetode
KR960700746A (ko) 헬리코박터 피롤리 관련 위십이지장 질환의 치료 방법(treatment of h. pylori associated gastroduodenal disease)
DK69685A (da) Oralt praeparat, der indeholder allergen
AU1370088A (en) Use of antigenic substances for the prophylaxis or therapy of disorders and diseases within the gastrointestinal tract of animals and humans
AR010031A1 (es) Vacuna oral para animales
DE3877365D1 (de) Arzneimittel mit methylcellulose.
SE8705136D0 (sv) Oral doseringsenhet for lekemedel och dess anvendning och framstellning
CA2133108A1 (fr) Vaccin a base de toxoide contre pasteurella haemolytica type a-1
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
GB2314334A (en) Improved production of antibodies through the use of antigen antibody complexes
ZA881081B (en) Virus antigen,method for its preparation and its use for diagnostic and therapeutic purposes(vaccines)
Ganguly et al. Cell-mediated immunity on secretory surfaces
Wasinski et al. Effect of antibiotics on the immune response of pigs against erysipelas suum vaccinated against swine fever, erysipelas and colibacillosis.
Georgadze et al. Development and testing of antistaphylococcal heterogenous gamma globulin.